<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856166</url>
  </required_header>
  <id_info>
    <org_study_id>9147</org_study_id>
    <nct_id>NCT01856166</nct_id>
  </id_info>
  <brief_title>PIEB-PCEA Versus CEI-PCEA for Labor Analgesia in Nulliparous</brief_title>
  <acronym>PIEB</acronym>
  <official_title>Programmed Intermittent Epidural Bolus Coupled With PCEA (PIEB-PCEA) Versus Continuous Epidural Infusion Coupled With PCEA (CEI-PCEA) for Labor Analgesia in Nulliparous: Effects on Labor Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidural analgesia still have an impact on obstetric outcomes and especially on instrumented
      delivery rates.

      To assess the best maintainance regimen of epidural analgesia during labor the investigators
      plan to include 300 nulliparous in this multicenter randomized, double blind trial. The
      primary outcome will be a composite set of criteria that can lead to instrumented delivery.
      Secondary outcome will focus on analgesia motor block and satisfaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be informed during the anaesthetic consultation and recruited at the beginning
      of the labor if they comply with inclusion criteria. Habitual proceedings of the placing and
      induction of epidural analgesia (Local Anaesthetics (AL): Levobupivacaine 0.100% 15mL
      Sufentanil 10µg). Patients who will not obtain at 30min a pain score &lt; 1/10 will be excluded
      (epidural analgesia not functional). The upkeep of analgesia will be provided by an automatic
      pump and randomized in: classic pump and new pump. The mixture used will be the same in the 2
      groups: Levobupivacaine 0.0100% + Sufentanil 0.5µg/mL. The classic pump administers AL with a
      continuous output (8mL/h)even though the new pump administers AL in bolus (8mL every hour;
      beginning 1h after the induction). The classic pump is a pump CADD SMITHS PCEA (Patient
      Controlled Epidural Analgesia) with the programming: continuous output 8mL/h; Additional
      bolus if necessary: 8mL; Maximal dose by hour: 24mL.

      The new pump is a pump CADD SMITHS called PIEB (Programmed Intermittent Epidural Bolus) with
      the programming: intermittent bolus 8mL every hour; Additional bolus if necessary: 8mL; Ban
      period during 10min between patient bolus and automatic bolus; Maximal dose by hour: 24mL.

      In case of the pain reappears and which is not calmed with 2 successive patient bolus, the
      anaesthetist will be called for the evaluation and administration of a doctor bolus if
      necessary (Levobupivacaine 0.125% 5mL associated with 50µg of Clonidine).

      Collected data will be demographic data, data about the obstetrical labor proceedings, data
      about pain, motor block, maternal satisfaction, total quantity of administered analgesia,
      number of patient and doctor bolus wich are asked and administered and neonatal data.

      Endpoints will be collected by a doctor in blind of the type of pump (the 2 pumps are the
      same extern aspect, only the intern programming is different).

      In case of caesarean during the labor, patient will be excluded of the study. When a decision
      of extraction will be taken, patient will receive a bolus of AL according to the anaesthetist
      decision but not accounted for the dose calculation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of a specific clinical criteria which can lead to a complication of the delivery</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Specific clinical criteria are:
Type of posterior engagement
Type of posterior extrication
Duration of waiting at complete dilatation &gt; 3 hours
Duration of expulsive efforts &gt; 40 minutes
Foetal bradycardia &lt; 100 BPM during 1 minute at least</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Instrumental delivery rate</measure>
    <time_frame>up to 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain during the end of labor</measure>
    <time_frame>up to 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacity of epidural analgesia</measure>
    <time_frame>up to 10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacity of epidural analgesia</measure>
    <time_frame>up to 10 hours</time_frame>
    <description>Efficacity of epidural analgesia is defined by a EVN score &lt; 3 at several times of delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of motor block</measure>
    <time_frame>Up to 10 hours</time_frame>
    <description>Presence of motor block is estimated with Bromage and Straigh Raising leg scales.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>CEI-PCEA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous Epidural Infusion coupled with Patient Controlled Epidural Analgesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIEB-PCEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Programmed Intermittent Epidural Bolus coupled with Patient Controlled Epidural Analgesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Release analgesia by CADD SMITHS PCEA pump</intervention_name>
    <description>Analgesia will be release by continuous manner with an automatic pump</description>
    <arm_group_label>CEI-PCEA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Release analgesia by CADD SMITHS PIEB pump</intervention_name>
    <description>Analgesia will be release by bolus with an automatic pump</description>
    <arm_group_label>PIEB-PCEA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <arm_group_label>CEI-PCEA</arm_group_label>
    <arm_group_label>PIEB-PCEA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <arm_group_label>CEI-PCEA</arm_group_label>
    <arm_group_label>PIEB-PCEA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nulliparous patient with a spontaneous labor at full term, from a normal pregnancy,
             carrier a singleton in cephalic position, with a distension &lt;4cm and eligible for an
             epidural analgesia

          -  Patient has signed informed consent

          -  Patient affiliated or beneficiary of a social medical insurance

          -  Patient aged between 18 and 44 years old

        Exclusion Criteria:

          -  Morphinic administration before the care

          -  Anomaly of fetal cardiac rate

          -  Fetal or maternal anomalies wich don't allow to evaluate motor block

          -  Known uterine malformation

          -  Contraindications for thrusts for pregnancy

          -  Patient protected by law

          -  Patient under guardianship
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Estelle MORAU, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Montpellier - Department of gynaecology and obstetric</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Estelle MORAU, MD</last_name>
    <phone>0665849512</phone>
    <email>e-morau@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique CHASSARD, MD PhD</last_name>
      <phone>0472129763</phone>
      <email>dominique.chassard@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique CHASSARD, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine BONNIN, MD</last_name>
      <phone>0472129763</phone>
      <email>mbonnin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Martine BONNIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte STORME, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan BENHAMOU, MD-PHD</last_name>
      <email>dan.benhamou@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Dan BENHAMOU, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle MORAU, PhD</last_name>
      <phone>0665849512</phone>
      <email>e-morau@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claire CHAUVETON</last_name>
      <phone>0467330924</phone>
      <email>c-chauveton@chu-montpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>MORAU Estelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélien BONNAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal COLSON, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques DUBOURDIEU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles LEGOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie BARBIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nulliparous</keyword>
  <keyword>Singleton</keyword>
  <keyword>delivery</keyword>
  <keyword>pregnancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

